Remove tag scottish-medicines-consortium
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least two prior antiseizure medicines.

article thumbnail

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

pharmaphorum

Evrysdi was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in May, a couple of months after the drug also got a green light in the EU. million price tag make it is the most expensive treatment ever approved for NHS funding.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

pharmaphorum

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year.

Hospitals 111
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Access to oncology medicines varies across countries, and their cost against safety/efficacy is generally perceived as being low, such as in the US. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105